Towards better personalized care in rheumatoid arthritis.
作者信息
Taylor Peter C
机构信息
Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.
出版信息
Rheumatology (Oxford). 2025 Mar 1;64(Supplement_2):ii1-ii2. doi: 10.1093/rheumatology/keaf026.
Abstract
摘要
相似文献
1
Towards better personalized care in rheumatoid arthritis.迈向类风湿关节炎更优质的个性化治疗。
Rheumatology (Oxford). 2025 Mar 1;64(Supplement_2):ii1-ii2. doi: 10.1093/rheumatology/keaf026.
2
Viewpoint: Could better understanding of risk factors for comorbidities pave the way towards personalized therapy in rheumatoid arthritis?观点：更好地了解合并症的风险因素是否能为类风湿关节炎的个体化治疗铺平道路？
Rheumatology (Oxford). 2023 Oct 23;62(SI3):SI271-SI273. doi: 10.1093/rheumatology/kead352.
3
Personalized Risk Estimator for Rheumatoid Arthritis (PRE-RA) Family Study: rationale and design for a randomized controlled trial evaluating rheumatoid arthritis risk education to first-degree relatives.类风湿关节炎个性化风险评估器（PRE-RA）家族研究：一项评估向一级亲属进行类风湿关节炎风险教育的随机对照试验的原理与设计
Contemp Clin Trials. 2014 Sep;39(1):145-57. doi: 10.1016/j.cct.2014.08.007. Epub 2014 Aug 20.
4
Individualized Drug Repositioning For Rheumatoid Arthritis Using Weighted Kolmogorov-Smirnov Algorithm.使用加权柯尔莫哥洛夫-斯米尔诺夫算法进行类风湿性关节炎的个体化药物重新定位。
Pharmgenomics Pers Med. 2019 Dec 11;12:369-375. doi: 10.2147/PGPM.S230751. eCollection 2019.
5
Towards prevention of autoimmune diseases: The example of rheumatoid arthritis.迈向自身免疫性疾病的预防：以类风湿关节炎为例。
Eur J Immunol. 2021 Aug;51(8):1921-1933. doi: 10.1002/eji.202048952. Epub 2021 Jul 3.
6
Translational strategies to implement personalized medicine: rheumatoid arthritis examples.实施个性化医疗的转化策略：类风湿关节炎实例
Per Med. 2009 Jul;6(4):429-437. doi: 10.2217/pme.09.17.
7
Molecular and Cellular Heterogeneity in Rheumatoid Arthritis: Mechanisms and Clinical Implications.类风湿关节炎中的分子和细胞异质性：机制和临床意义。
Front Immunol. 2021 Nov 25;12:790122. doi: 10.3389/fimmu.2021.790122. eCollection 2021.
8
Therapeutic advances in rheumatoid arthritis.类风湿关节炎的治疗进展。
BMJ. 2024 Jan 17;384:e070856. doi: 10.1136/bmj-2022-070856.
9
Pharmacogenetics of disease-modifying antirheumatic drugs in rheumatoid arthritis: towards personalized medicine.疾病修饰抗风湿药物在类风湿关节炎中的药物遗传学：迈向个体化医学。
Pharmacogenomics. 2013 Mar;14(4):425-44. doi: 10.2217/pgs.13.22.
10
Effect of communicating personalized rheumatoid arthritis risk on concern for developing RA: A randomized controlled trial.沟通个体化类风湿关节炎风险对关注自身罹患类风湿关节炎的影响：一项随机对照试验。
Patient Educ Couns. 2019 May;102(5):976-983. doi: 10.1016/j.pec.2018.12.011. Epub 2018 Dec 10.
本文引用的文献
1
Deconstruction of rheumatoid arthritis synovium defines inflammatory subtypes.类风湿关节炎滑膜的解构定义了炎症亚型。
Nature. 2023 Nov;623(7987):616-624. doi: 10.1038/s41586-023-06708-y. Epub 2023 Nov 8.
2
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update.EULAR 推荐的类风湿关节炎治疗方案：使用合成和生物疾病修正抗风湿药物：2022 更新版。
Ann Rheum Dis. 2023 Jan;82(1):3-18. doi: 10.1136/ard-2022-223356. Epub 2022 Nov 10.
3
Managing inadequate response to initial anti-TNF therapy in rheumatoid arthritis: optimising treatment outcomes.应对类风湿关节炎初始抗TNF治疗反应不足：优化治疗效果
Ther Adv Musculoskelet Dis. 2022 Aug 16;14:1759720X221114101. doi: 10.1177/1759720X221114101. eCollection 2022.
4
Call for action: incorporating wellness practices into a holistic management plan for rheumatoid arthritis-going beyond treat to target.行动呼吁：将健康实践纳入类风湿关节炎的整体管理计划——超越治疗目标。
RMD Open. 2021 Dec;7(3). doi: 10.1136/rmdopen-2021-001959.
5
Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial.利妥昔单抗与托珠单抗治疗抗 TNF 应答不足的类风湿关节炎患者（R4RA）：分层、基于活检、多中心、开放标签、4 期随机对照临床试验的 16 周结果。
Lancet. 2021 Jan 23;397(10271):305-317. doi: 10.1016/S0140-6736(20)32341-2.
6
Molecular Portraits of Early Rheumatoid Arthritis Identify Clinical and Treatment Response Phenotypes.早期类风湿关节炎的分子特征可识别临床和治疗反应表型。
Cell Rep. 2019 Aug 27;28(9):2455-2470.e5. doi: 10.1016/j.celrep.2019.07.091.
7
Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study.妊娠期间培塞丽珠（certolizumab pegol）胎盘转移缺失：来自 CRIB 的前瞻性上市后药代动力学研究结果。
Ann Rheum Dis. 2018 Feb;77(2):228-233. doi: 10.1136/annrheumdis-2017-212196. Epub 2017 Oct 13.
8
Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force.类风湿关节炎达标治疗：国际特别工作组2014年推荐意见更新
Ann Rheum Dis. 2016 Jan;75(1):3-15. doi: 10.1136/annrheumdis-2015-207524. Epub 2015 May 12.
9
Inequities in access to biologic and synthetic DMARDs across 46 European countries.46 个欧洲国家生物制剂和合成改善病情抗风湿药物获取机会的不平等现象。
Ann Rheum Dis. 2014 Jan;73(1):198-206. doi: 10.1136/annrheumdis-2012-202603. Epub 2013 Mar 6.
10
B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: a six-month, national, multicenter, open-label study.B细胞活化生物标志物作为类风湿关节炎患者对利妥昔单抗反应的预测因素：一项为期6个月的全国性多中心开放标签研究。
Arthritis Rheum. 2011 Apr;63(4):933-8. doi: 10.1002/art.30233.
Zotero 插件